Replimune Group, Inc. — Form 8-K Summary
Reporting event: Current report relating to leadership and employment-agreement changes. The filing identifies March 21, 2024 as the earliest event date, while the described announcements and agreements occurred on March 25–26, 2024.
Business Context and Period
Replimune Group, Inc. is a Delaware biotechnology company headquartered in Woburn, Massachusetts, with common stock trading on Nasdaq under the symbol REPL. The company is an emerging growth company. This filing does not report quarterly or annual operating results.
Key Financial and Operating Metrics
- The filing provides no revenue, net income, loss, cash flow, margin, debt, liquidity, cash balance, or other operating-performance metrics.
- Dr. Sushil Patel’s initial annual base salary as chief executive officer is $600,000, with a target annual discretionary bonus of 60% of base salary.
- Philip Astley-Sparke’s initial annual base salary as executive chairman is $268,686, with a target annual discretionary bonus of 60% of base salary. He is expected to devote an average of 40% of his working hours, and at least 20 hours per week, to the company.
Material Changes and Leadership Transitions
- Effective April 1, 2024, Dr. Sushil Patel will become chief executive officer and join the board as a Class III director.
- Philip Astley-Sparke will transition from chief executive officer to executive chairman of the board.
- Dieter Weinand will transition from board chair to lead independent director.
- Dr. Robert Coffin will transition to an advisory role as founder and chief scientist effective April 1, 2024.
- Chief operating officer Dr. Colin Love will retire effective May 31, 2024.
- Chief business officer Dr. Pamela Esposito and chief development operations officer Tanya Lewis will leave their executive positions and continue in advisory capacities.
- Paul Bullock will become chief manufacturing officer effective April 1, 2024.
Employment Agreements, Outlook, and Risks
- Replimune entered into amended and restated employment agreements with Dr. Patel and Mr. Astley-Sparke.
- Each agreement provides severance equal to one year of base salary, plus continued COBRA coverage, following certain qualifying terminations without cause or for good reason.
- Following a qualifying termination within 12 months after a change in control, each executive may receive two times base salary plus the target annual bonus, paid over 24 months, together with COBRA coverage, subject to customary conditions including a release.
- The agreements contain customary confidentiality, noncompetition, and nonsolicitation provisions. They also include a Section 280G tax-protection provision under which payments are reduced only when doing so produces a greater after-tax benefit.
- The filing provides no formal financial guidance, clinical guidance, product outlook, or updated cash-runway information.
Important Facts for Investors to Verify
- Confirm the effective dates and completion of the CEO and broader executive leadership transitions.
- Review the full employment agreements and potential severance, change-in-control, COBRA, and equity-compensation obligations.
- Assess whether the leadership changes affect clinical development, regulatory, manufacturing, or commercialization plans.
- Consult the company’s latest periodic filing for cash, liquidity, operating expenses, loss trends, debt, and development-program updates, none of which are provided in this 8-K.
- Note the apparent timing discrepancy between the stated earliest event date of March 21, 2024 and the March 25–26 dates described in the filing.